Message :
Required fields The application includes robust data from the Phase 3
registration program, which demonstrated efficacy of daridorexant on
objective and subjective sleep parameters, and an improvement in daytime
functioning, while maintaining a favorable safety profile Allschwil, Switzerland March 10, 2021 Idorsia Ltd (SIX: IDIA) today announced that the US Food and Drug
Administration (FDA) has accepted the new drug application (NDA) for
review of Idorsia s investigational dual orexin receptor antagonist,
daridorexant, for the treatment of adult patients with insomnia. Insomnia is a common problem with approximately 25 million adults in the
US who meet the diagnostic criteria. Insomnia, a condition of overactive